Osaka: Recently, Japanese experts have investigated the positive effects of the diabetes drug dapagliflozin on heart failure patients.
Heart failure is a condition in which the heart is unable to pump blood around the body properly.
The Japanese experts focused the research on how the aforementioned drug affects the test of a specific biomarker UACR (urine albumin to creatinine ratio) in the urine.
The research was led by Dr. Fumiki Yoshihara at the National Cerebral and Cardiovascular Center in Osaka, Japan. The researchers wanted to see if dapagliflozin could improve UACR levels in patients with heart failure and type 2 diabetes.
The study included 146 patients who were given 5 mg of dapagliflozin daily for 2 years. The researchers found that the drug had no significant effect on UACR, but that the drug was helpful in some heart-related problems.
The drug reduced the volume of the left ventricle of the heart. Because left ventricular enlargement can be a problem in terms of heart failure. In addition, patients also experienced fewer serious cardiac events, such as the need to go to the hospital in an emergency.
(function(d, s, id){
var js, fjs = d.getElementsByTagName(s)[0];
if (d.getElementById(id)) {return;}
js = d.createElement(s); js.id = id;
js.src = “//connect.facebook.net/en_US/sdk.js#xfbml=1&version=v2.3&appId=770767426360150”;
fjs.parentNode.insertBefore(js, fjs);
}(document, ‘script’, ‘facebook-jssdk’));
(function(d, s, id) {
var js, fjs = d.getElementsByTagName(s)[0];
if (d.getElementById(id)) return;
js = d.createElement(s); js.id = id;
js.src = “//connect.facebook.net/en_GB/sdk.js#xfbml=1&version=v2.7”;
fjs.parentNode.insertBefore(js, fjs);
}(document, ‘script’, ‘facebook-jssdk’));